Please login to the form below

Not currently logged in
Email:
Password:

darapladib

This page shows the latest darapladib news and features for those working in and with pharma, biotech and healthcare.

GSK takes anti-inflammatory drug into phase III as heart therapy

GSK takes anti-inflammatory drug into phase III as heart therapy

GSK's cardiovascular pipeline suffered a setback last month when coronary artery disease therapy darapladib failed a second phase III trial.

Latest news

  • Second darapladib failure disappoints GSK Second darapladib failure disappoints GSK

    Drug unable to demonstrate effectiveness in acute coronary syndrome. Prospects for GlaxoSmithKline's coronary artery disease therapy darapladib have all but disappeared after it failed to show efficacy in a second ... Top-line results from the SOLID-TIMI

  • Moving parts Moving parts

    Meanwhile, costly phase III failures arrived in the shape of Lilly's depression drug edivoxetine and GlaxoSmithKline's highly anticipated new coronary heart disease drug candidate darapladib, which both flunked

  • GSK hit as darapladib flunks phase III test GSK hit as darapladib flunks phase III test

    Heart disease drug disappoints in late-stage trial.  . GlaxoSmithKline's highly anticipated new coronary heart disease (CHD) drug candidate darapladib has disappointed in a phase III trial. ... will continue to examine the data and wait for the results

  • GSK's Chinese sales hit by scandal, say analysts GSK's Chinese sales hit by scandal, say analysts

    darapladib for atherosclerosis which could have "vast potential" if it reaches the market.

  • GSK submits albiglutide for European approval GSK submits albiglutide for European approval

    Albiglutide is, along with lupus treatment Benlysta and heart disease drug darapladib, one of a trio of drugs GSK has developed with Human Genome Sciences.

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Pharma deals during July 2012 Pharma deals during July 2012

    These are Benlysta (belimumab), an antibody approved for the treatment of lupus; darapladib, a phase III small molecule drug for the treatment of cardiovascular disease; and albiglutide, an albumin-fusion protein ... There is $150m in potential licence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
July 2020: diversity and inclusion in clinical trials round-up
COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020
In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...

Infographics